Plain-English translation of NCT07198074 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether adding —a medication that blocks blood vessel growth in tumors—to a combination of chemotherapy ( and ) and an immunotherapy drug () can help people with advanced or recurrent endometrial cancer live longer and stay healthier. You'll be randomly assigned to receive one of three treatment combinations, and researchers will compare how well each one works.
Endometrial cancer with certain genetic changes (pMMR and TP53 mutations) tends to be more aggressive and harder to treat. Doctors want to know if adding to existing treatments can improve outcomes for these patients.
You likely qualify if…
You likely don't qualify if…
You'll receive intravenous medications (through an IV) on the first day of each 3-week cycle for 6 to 10 cycles. Each treatment day involves receiving three drugs over a few hours. After the initial treatment phase, you may continue with maintenance immunotherapy every 6 weeks for up to 14 additional cycles. Throughout the trial, you'll have blood tests, urine tests, and imaging scans (CT or MRI) to monitor how your cancer is responding.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States